Kornimate/medical-research-clean huggingface dataset:
continue glucose monitoring before insulin pump

Conditions: Type 1 Diabetes Mellitus

Summary: the purpose of the study is to learn more about blood glucose control when people with type 1 diabetes switch to an insulin pump. the investigators hope to learn whether using a continuous glucose monitor (cgm) helps to create personalized insulin doses that may lead to stable blood glucoses and less frequent insulin pump dose changes during the transition to an insulin pump.

this is a prospective, randomized controlled study. participants will be asked to wear a medtronic ipro2 continuous glucose monitor (cgm) 1-2 weeks prior to starting on insulin pump therapy. depending on randomization groups, participants will either have cgm data used inform starting insulin pump doses (treatment group), or to standard of care for starting on insulin pump (control group). participants will wear the cgm again during the first 5 days of pump start and at approximately 6 weeks after pump start, in order to collect blood glucose data. each time the cgm is worn, blood glucoses must be checked 6-8 times daily, and a written log must be completed. baseline medical information also will be collected at the start of participation. participants will also be asked to complete a questionnaire at approximately 6 weeks after pump start. participation in the study will be complete after a standard of care follow up visit approximately 3 months after pump start.

Eligibility criteria:
inclusion criteria: 1. males and females aged 2-24 years 2. clinical diagnosis of type 1 diabetes mellitus 3. duration of diabetes: at least 6 months - this will ensure some glycemic stability prior to study, and most children do not start on an insulin pump until about 6 months into their diagnosis. 4. basal/bolus insulin regimen using long-acting and rapid-acting insulin - this will provide a uniform method of insulin therapy. 5. willingness to perform at least 6-8 capillary blood glucose tests per day while wearing the ipro®2 6. willingness to wear the ipro®2 for 5 days continuously per insertion 7. participant agrees to comply with the study protocol requirements 8. informed consent, assent, hipaa authorization, and california experimental subject bill of rights signed by the participant and/or parent guardian exclusion criteria: 1. comorbid conditions, including but not limited to cystic fibrosis, oncologic processes, other systemic diseases that may affect overall glycemic control 2. glucocorticoid use within 2 weeks of study enrollment 3. concurrent use of other medications that may affect glycemic control 4. prior cgm use in the past 6 months 5. the participant has any skin abnormality (e.g. psoriasis, rash, staphylococcus infection) in the area of ipro®2 placement that has not been resolved at the time of enrollment and would inhibit the participant from wearing the ipro®2. 6. non-english or non-spanish speaking

Keywords: cgm
implementing ehealth interventions into regular clinical practice

Conditions: Renal Transplant Recipients; Non-functioning Pituitary Adenoma

Summary: the purpose with this study is to test a digital patient-provider communication tool for symptom and needs management among patients with chronic health conditions.

living with chronic health conditions affects all areas of life. fatigue, sleeping problems, pain and loneliness are common. in addition to troublesome symptoms that vary in intensity, many experience worry and uncertainty. there is a need to improve the quality of follow-up of patients with chronic health conditions. a digital patient-provider communication tool, which supports shared decision making, can be one way to improve quality. the digital tool (involveme) will provide patients with the opportunity to complete and submit a symptom and need assessment prior to out-patient visits at the hospital. also, patients will have the opportunity to use secure e-mail for follow-up from health care providers in between hospital visits. the assessment will allow patient to prioritize what is important to talk with their health care providers about. such a tool can help to make changes in symptoms more visible to both patients and health care providers, as well as make it easier to ask for information and guidance to deal with the individual difficulties patients' experience. the goal is to better address symptoms and concerns and to enhance follow up and coordination between consultations as well as increase the quality of life and reduce illness related stress. the digital communication tool is tested in a feasibility pilot study, including 23 patients with non-functioning pituitary adenomas. participants will be given the opportunity to use the digital communication tool with baseline measures and following measures after 3 months.

Eligibility criteria:
inclusion criteria: * patients with non functioning pituitary adenomas (nfpa) * able to read and speak norwegian * have access to a smart-phone or tablet * have their own secure access device (bankid). exclusion criteria: * n/a

Keywords: symptom assessment ehealth implementation communication shared decision making
halliwick concept on motor functions in spastic cp

Conditions: Spastic Cerebral Palsy; Spastic Hemiplegic Cerebral Palsy

Summary: this randomized controlled trial will investigate the effect of hydrotherapy (halliwick concept) on motor functions in children with spastic cerebral palsy (cp). minimum of 30 spastic cp children will be recruited for this study. children will be randomly assigned into control group who will receive conventional selected exercise treatment or study group who will receive the same conventional program in addition to underwater exercise program. motor function will be evaluated at baseline and after 3 months of treatment. no potential harms are expected during this study.


Eligibility criteria:
inclusion criteria: * children from both sexes diagnosed with spastic cp according to a pediatrician * the degree of spasticity will be determined as grade two or less according to modified ashworth scale * their age will range from five to nine years * intelligence quotient score \> 35 (no worse than moderate intellectual disability) as assessed via wechsler test scales * no severe psychosocial or behavioral problems, such high aggression or risk of self-harm. exclusion criteria: * initiation of oral antispastic medication * botulinum toxin injections or surgery performed less than 90 days before enrollment * severe visual or auditory impairment * uncontrollable epilepsy (defined as the occurrence of seizures despite the use of at least one antiepileptic drug) * open wounds * children with a psychiatric disorder * cognitive disorders evaluated by the pediatric evaluation of disability inventory * uncontrolled epilepsy * active infection * severe cardiopulmonary disorders.
hpv educational intervention to increase acceptance and completion of free hpv vaccination among underserved adults

Conditions: Human Papillomavirus Infection; Human Papillomavirus-Related Carcinoma

Summary: this phase iv trial examines the impact of an education program on the human papilloma virus (hpv) and its effects on the acceptance and completion rates of a free hpv vaccination program in underserved adult patients. participating in the hpv educational program may increase the hpv vaccination rates among low income uninsured adult patients and ultimately prevent hpv related cancers.

primary objectives: i. determine the acceptability and completion rates of free hpv vaccination among the underserved adult patients at the volunteer in medicine clinic (vim) in jacksonville, florida. ii. determine if an education program on hpv vaccination increases the acceptability of free hpv vaccination among the underserved adult patients at the volunteer in medicine clinic (vim) in jacksonville, florida. iii. determine the baseline prevalence of hpv vaccination completion rates among vim patients age 18-45. iv. determine if there are differences in acceptance and completion rates of hpv vaccination, among vim patients of different sex, age (18-26 versus \[vs\] 27-45), ethnicity or race, following an education program on hpv as part of this protocol participation. vi. assessing possible barriers for vaccine series completion. vii. determine if follow up intervention increases completion rate of free hpv vaccine series within 9 months. outline: patients receive educational materials on hpv and are asked of their willingness to proceed with the first hpv vaccination. patients who express interest in receiving the hpv vaccination, then receive the first dose of the hpv vaccine and the next 2 doses approximately 2 months and 6 months following the initial vaccine.

Eligibility criteria:
inclusion criteria: * male and female adults patients seen at volunteers in medicine ages 18-45 years of age who read and understand english or spanish exclusion criteria: * children (under 18 years of age) * individuals who had previously received any dose of hpv vaccine
digital solutions in heart therapy (dignity)

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: this study aims to assess the safety and effectiveness of telemedicine guided strategy on guideline-directed medical therapy (gdmt) optimization in hospitalized patients with heart failure in comparison to usual care in switzerland.

heart failure (hf) is a chronic condition affecting approximately 26 million people worldwide, with acute decompensations leading to frequent hospitalizations and increased mortality. while guideline-directed medical therapy (gdmt) has been shown to improve outcomes in hf with reduced ejection fraction (hfref), real-world data indicate suboptimal implementation, with delayed initiation and low adherence to target doses. the strong-hf study demonstrated that rapid up-titration of gdmt following hospitalization significantly reduces hf-related mortality and readmission, highlighting the importance of early and structured treatment optimization. however, close monitoring during the vulnerable post-discharge phase remains resource-intensive and difficult to implement in routine care. the dignity study aims to assess the safety and effectiveness of a telemedicine-guided strategy for optimizing gdmt in patients with hfref compared to usual care in switzerland after discharge. the study hypothesizes that telemedicine-supported management will improve gdmt optimization and clinical outcomes in this high-risk patient population.

Eligibility criteria:
inclusion criteria: 1. age \> 18 years at the time of hospital admission 2. ability to use a (smart)phone and/or tablet for the follow-up 3. documented left ventricular ejection fraction (lvef) \> 40% assessed within preceding 12 months 4. not treated with optimal doses of oral hf therapies within 2 days before anticipated hospital discharge for acute hf in at least one of the medication categories (for details see table 1 on page 10) 5. hospitalized due to acute hf decompensation. 6. specific measures within 24 hours prior to randomization * systolic blood pressure \> 100 mmhg, and heart rate \> 60bpm * serum potassium \< 5mmol/l exclusion criteria: 1. inability to use a (smart)phone or tablet 2. clear intolerance to high doses of betablockers, ace inhibitors, or arbs 3. estimated glomerular filtration rate \<30ml/min/1.73m2 or dialysis 4. myocardial infarction, unstable angina or cardiac surgery within 3 months, percutaneous transluminal coronary intervention within 1 months prior to screening 5. cardiac resynchronization therapy device implantation within 3 months prior to screening 6. presence of significant obstructive lesion of the left ventricular outflow tract 7. amyloid cardiomyopathy 8. pregnant or nursing women

Keywords: guideline-directed medical therapy telemedicine
chinese pediatric massage on children with acute diarrhea: a randomized sham massage controlled trial

Conditions: Diarrhea

Summary: the purpose of this study is to evaluate the efficacy of chinese pediatric massage as an add-on therapy while comparing with sham massage both on the basis of usual care for 0-6 years old children with acute diarrhea.

chinese pediatric massage has been practised as an option for the treatment of pediatric diarrhea for hundreds of years (since ming dynasty). the history of chinese pediatric massage for health promotion is much longer, it can be traced back to more than one thousand years ago (652 ad). many of the acupoints adopted in chinese pediatric massage are unique if it is compared with those for adult massage. the manipulation is found to be easily accepted by children, as the strength of massage is gentle and soft. no severe adverse reaction in regards of chinese pediatric massage was reported, the mild adverse reaction such as skin abrasion can be completely avoided with correct operating instructions.

Eligibility criteria:
inclusion criteria: 1. subject's symptoms meet the diagnosis criteria of acute diarrhea. 2. the occurrence of diarrhea is no more than 72 hours. 3. stool frequency is equal or more than 5 times a day. 4. subject has not been involved in any other clinical trials at the same period of time. 5. subject's guardian may coordinate during the clinical trial. 6. subject's guardian have signed the informed consent. exclusion criteria: 1. a history of experiencing chinese pediatric massage on hands 2. subject has cholera or malaria 3. subject with the following conditions on the manipulating part: phlebitis，open wound，fracture，tissue damage 4. subject has the follow complications: severe dehydration，metabolic acidosis，disorders of consciousness, seizures or twitching, shock, azotemia

Keywords: pediatric massage tuina therapy acute diarrhea
physical activity and physical fitness parameters in covid-19 lockdown

Conditions: Assessment, Self

Summary: in this study; it was aimed to compare the physical activity levels of students who continued their university education face-to-face before the covid-19 lockdown, and the values of physical activity levels related to health, physical activity levels and health-related physical fitness parameters in the post-lockdown period.

within the scope of the course, the demographic information of the students will be recorded and physical activity status, physical fitness parameters, muscle endurance, cardiovascular endurance, flexibility and body composition will be evaluated.

Eligibility criteria:
inclusion criteria: * before the quarantine period, those who completed the physical activity level and physical fitness tests within the scope of physical activity i course * students who do not have any physical or mental problems for the tests and measurements to be applied exclusion criteria: * no internet access, * students who have an obstacle to taking tests and measurements
standard or convalescent plasma in patients with recent onset of covid-19 respiratory failure

Conditions: COVID-19

Summary: to date no specific treatment has been proven to be effective for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection. it is possible that convalescent plasma that contains antibodies to sars-cov-2 might be effective against the progression of infection. promising results have been shown by preliminary data from china cases. the investigators planned to compare effectiveness of adding covid-19 convalescent plasma to standard therapy protocol (stp) versus adding plasma donated in pre-covid era versus stp alone in patient with covid-19 within 5 days from the onset of respiratory distress. stp at enrolment is the best evidence based therapy approved for treatment of covid patients by regional health system emergency committee.

500-700 ml of plasma will be collected by apheresis from covid recovered donors showing the presence of neutralizing antibodies to sars-cov-2 (anti-sars-cov-2). all plasma will be screened for transmissible diseases according to italian law (hepatitis b virus,hepatitis c virus, human immunodeficiency virus 1-2, syphilis) plus adjunctive screening for hepatitis a virus and hepatitis e virus-rna and parvovirus b19-dna as requested from italian national blood authority. apheresis will be divided in two/three units (170-300 ml each), virus inactivated with riboflavin and ultraviolet light illumination technology and immediately frozen and stored separately from other plasma bags. enrolled patients will be stratified according to severity of respiratory failure and randomized in three arms: 1) standard therapy protocol (stp), 2) standard therapy protocol + 170-350 ml standard plasma (sp) on day 1-3-5 after randomization, 3) standard therapy protocol + 170-350 ml covid-19 convalescent plasma on day 1-3-5 after randomization. the three therapeutic units of covid-19 convalescent plasma will be chosen in order to minimize variations among patients in the total amount of infused sars-cov-2 antibodies.

Eligibility criteria:
inclusion criteria: * confirmed sars-cov-2 diagnosis by rt-pcr on nasopharyngeal swab or on bronchoalveolar lavage * respiratory failure onset or progression within 5 days * signed informed consent exclusion criteria: * pregnancy * previous severe reactions to plasma transfusion * unavailability of blood group compatible covid-19 convalescent plasma
mindfulness-oriented recovery enhancement (more) for cancer pain relief

Conditions: Chronic Pain; Cancer Pain

Summary: the purpose of this study is to evaluate whether or not mindfulness-based interventions/mbis may help reduce chronic pain in participants who have cancer-related chronic pain. mbis are therapeutic programs that use mindfulness meditation practices to help people focus on the present moment, as well as encourage acceptance of thoughts, emotions, and body sensations. the researchers think that an mbi treatment called mindfulness-oriented recovery enhancement (more) may help people who are experiencing cancer-related chronic pain.


Eligibility criteria:
inclusion criteria: * english speaking * age ≥ 18 years or older * a history of cancer with no restrictions placed on type of cancer * determined to be either no-evidence of disease or stable oncological disease by referring or study physicians/advanced practice providers * having a pain (musculoskeletal, generalized, or neuropathic) rating of 4 or greater in worst pain on a 0-10 numerical rating scale in the preceding week * having had pain for at least 3 months and at least 15 days with pain in the preceding 30 days * willing to adhere to all study-related procedures, including randomization to one of two treatment arms: more or wlc * ability to attend video-call session and a quiet/private location exclusion criteria: * active suicidality or schizophrenia * plan to initiate palliative radiation or interventional pain procedure within the next 12 weeks * cognitive impairment preventing completing pro independently or participate in virtual more as evaluated by study clinicians

Keywords: chronic pain cancer pain mindfulness-oriented recovery enhancement more mindfulness-based interventions mbis memorial sloan kettering cancer center 23-082
dfd01 spray hpa axis suppression study in adolescent patients with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: to evaluate the potential of dfd-01 (betamethasone dipropionate) spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (hpa) axis.

to evaluate the potential of dfd-01 (betamethasone dipropionate) spray, 0.05% to suppress the hypothalamic-pituitary-adrenal (hpa) axis when applied twice daily for 15 days or when applied twice daily for 29 days, in adolescent subjects with moderate to severe plaque psoriasis under maximal use conditions.

Eligibility criteria:
inclusion criteria: 1. subjects must weigh at least 55 pounds 2. subjects must present with a clinical diagnosis of stable (at least 3 months) plaque psoriasis. 3. subjects with psoriasis involving ≥ 10% bsa, not including the face, scalp, groin, axillae and other intertriginous areas.. 4. subjects must have moderate to severe plaque psoriasis at the baseline visit. 5. subjects whose results from the screening acth stimulation test are considered normal (cortisol level \>18 ug/dl at 30 minutes post stimulation) and show no other signs of abnormal hpa axis function or adrenal response. exclusion criteria: 1. current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis. 2. history of organ transplant requiring immunosuppression, hiv, or other immunocompromised state. 3. have received treatment for any type of cancer within 5 years of the baseline visit. 4. use within 60 days prior to the baseline visit of: 1) immunosuppressive drugs (e.g., tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea), or 3) biologic treatment for psoriasis (e.g., infliximab, adalimumab, etanercept, ustekinumab, secukinumab, or alefacept). 5. use within 30 days prior to the baseline visit of: 1) topical antipsoriatic drugs (salicylic acid, anthralin, coal tar, calcipotriene), 2) puva therapy, 3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine), or 4) uvb therapy. 6. use within 30 days prior to the screening visit of any product containing corticosteroids. inhaled, intraocular, intranasal, etc. steroids are not allowed. 7. subjects who have an abnormal sleep schedule or work overnight. 8. subjects with a known history of acute adrenal crisis, addison's disease or decreased adrenal output, low pituitary function or pituitary tumors. 9. subjects who have a history of an adverse reaction to cosyntropin injection or similar test reagents.